77470-53-2

Basic information

• Product Name: 4-CHLOROMETHYL-2-METHYLTHIAZOLE HYDROCHLORIDE
• Synonyms: BUTTPARK 45\02-17;4-(CHLOROMETHYL)-2-METHYL-1,3-THIAZOLE HYDROCHLORIDE;4-(CHLOROMETHYL)-2-METHYLTHIAZOLE HCL;4-CHLOROMETHYL-2-METHYLTHIAZOLE HYDROCHLORIDE;TIMTEC-BB SBB005574;4-(Chloromethyl)-2-methyl-1,3-thiazoleHCl;(4-(Chloromethyl)-2-methythiazole Hydrochloride);2-Methyl-4-(chloromethyl)thiazole Hydrochloride
• CAS NO: 77470-53-2
• Molecular Formula: C₅H₆ClNS*ClH
• Molecular Weight: 184.09
• Product Categories: Heterocycles;Sulfur & Selenium Compounds
• Mol File: 77470-53-2.mol
• Article Data: 5

Chemical Properties

• Melting Point: 161-163 °C
• Boiling Point: 217.5 °C at 760 mmHg
• Flash Point: 85.3 °C
• Appearance: Cream to gray-pink or brown/Crystalline Powder
• Storage Temp.: -20°C Freezer
• Solubility: DMSO, Methanol
• Sensitive: Lachrymatory
• CAS DataBase Reference: 4-CHLOROMETHYL-2-METHYLTHIAZOLE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLOROMETHYL-2-METHYLTHIAZOLE HYDROCHLORIDE(77470-53-2)
• EPA Substance Registry System: 4-CHLOROMETHYL-2-METHYLTHIAZOLE HYDROCHLORIDE(77470-53-2)

Safety Data

• Hazard Codes: C
• Statements: 34
• Safety Statements: 45-36/37/39-26
• RIDADR: 3261
• HazardClass: 8
• Hazardous Substances Data: 77470-53-2(Hazardous Substances Data)

Usage

Chemical Properties

Light-Yellow Oil

Uses

4-Chloromethyl-2-methyl-1,3-thiazole, Hydrochloride (cas# 77470-53-2) is a compound useful in organic synthesis.

Upstream product

• 62-55-5 thioacetamide 
• 534-07-6 1,3-Dichloroacetone 
• 22043-38-5 C₅H₈ClNOS*ClH 
• 21262-97-5 4-chloromethyl-2-methyl-4,5-dihydro-thiazol-4-ol 

Downstream Products

• 152147-43-8 methyl Z-4-[[2-butyl-5-[[1-butyl-3-[(2-methyl-4-thiazolyl)methyl]-2,5-dioxo-4-imidazolidinylidene]methyl]-1H-imidazol-1-yl]methyl]benzoate 
• 149168-09-2 methyl 3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(2-methylthiazol-4-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoate 
• 77470-54-3 4-[[1-(2,4-Dichlorophenyl)-2-(1H-imidazol-1-yl)-ethoxy]methyl]-2-methylthiazole, hydrochloride 
• 79387-05-6 4-[4-(4-Chlorobenzhydryl)piperazin-1-ylmethyl]-2-methylthiazole monofumarate 
• 13458-33-8 (2-methyl-4-thiazolyl)acetonitrile 
• 39238-07-8 4-(chloromethyl)-2-methyl-1,3-thiazole 
• 1442452-17-6 4-methyl-3-[2-methyl-4-(2-methyl-thiazol-4-ylmethoxy)-6-oxo-6H-pyrimidin-1-yl]-benzoic acid methyl ester 

Relevant articles and documents

Synthesis and promising in Vitro antiproliferative activity of sulfones of a 5-nitrothiazole series

The synthesis in water of new sulfone derivatives under microwave irradiation is described. This eco-friendly process leads to the expected products in good yields by reaction of various substituted sulfinates (commercially available or obtained by reduction of the corresponding sulfonyl chlorides) with 4-chloromethyl-2-methyl-5-nitro-1,3- thiazole. In order to evaluate the antiproliferative effect of these compounds, several sulfone derivatives are also dichlorinated on the Ca next to the sulfonyl group. An evaluation on different cancer cell lines reveals promising selective in vitro antiproliferative activity toward HepG2 human cell lines by dihydrogenated sulfones, suggesting further research should be to explore their anticancer potential in the treatment of liver cancer.

Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy

The structure-activity studies leading to the potent and clinically efficacious HIV protease inhibitor ritonavir are described. Beginning with the moderately potent and orally bioavailable inhibitor A-80987, systematic investigation of peripheral (P3 and P2') heterocyclic groups designed to decrease the rate of hepatic metabolism provided analogues with improved pharmacokinetic properties after oral dosing in rats. Replacement of pyridyl groups with thiazoles provided increased chemical stability toward oxidation while maintaining sufficient aqueous solubility for oral absorption. Optimization of hydrophobic interactions with the HIV protease active site produced ritonavir, with excellent in vitro potency (EC50 = 0.02 μM) and high and sustained plasma concentrations after oral administration in four species. Details of the discovery and preclinical development of ritonavir are described.

Imidazolylethoxymethyl derivatives of thiazole

New imidazolylethoxymethyl derivatives of thiazole are provided having the general formula STR1 wherein R1 is hydrogen, lower alkyl, lower alkoxy-lower alkyl, phenoxy-lower alkyl, phenyl-lower alkyl or substituted or unsubstituted phenyl; R2 is hydrogen or halogen; R3 and R4 are the same or different and are hydrogen, lower alkyl, lower alkoxy or halogen. The above compounds and their salts are useful as antifungal and antibacterial agents.